Wilms Tumour
From Kidney Cancer Resource
Contents |
Overview
Wilms tumor is also called Nephroblastoma and is a solid tumor of the kidney that arises from immature kidney cells. It is the fourth most common type of cancer in children.
Details
Solid Tumor: Wilms Tumor
Alternate Names: Nephroblastoma
Approximately 460 new cases of Wilms tumor are diagnosed each year in the United States, and 1 in 8,000-10,000 children are affected.
Average age at diagnosis is about three years, although older children and even adults are occasionally diagnosed with Wilms tumor.
Girls and boys are equally affected.
Other kidney cancers that are much less common than Wilms tumor occasionally arise in children. These tumors include clear cell sarcoma of the kidney, rhabdoid tumor of the kidney, renal cell carcinoma, undifferentiated sarcoma, and congenital mesoblastic nephroma. These tumors behave differently from Wilms tumor and require distinct treatments.
Influencing Factors:
Most children affected with Wilms tumor have no clear underlying cause for their disease. Several small studies have suggested that certain environmental factors may be associated with a higher risk of Wilms tumor, but the results were conflicting. A nationwide research study is underway to clarify whether exposure to drugs, chemicals, and infectious agents is associated with Wilms tumor. A few children are born with a genetic predisposition to Wilms tumor, which may reveal itself in several ways:
Congenital abnormalities:
It is well documented that certain syndromes, or clusters of inborn abnormalities, are associated with Wilms tumor. The syndromes associated with the greatest risk of Wilms tumor are the WAGR syndrome (Wilms tumor-aniridia-genitourinary malformation-retardation), the Denys-Drash Syndrome, and the Beckwith-Wiedemann Syndrome.
Familial Wilms tumor:
Approximately 1.5 percent of children with Wilms tumor have a relative who was also affected with Wilms tumor.
Bilateral Wilms tumor:
About 5-10 percent of patients with Wilms tumor have multiple tumors in one or both kidneys. Having multiple tumors does not indicate tumor spread. Rather, each tumor develops on its own, which reflects an underlying genetic predisposition to Wilms tumor.
Treatment Strategies
Treatment involves a combination of therapies that include surgery, chemotherapy, and, in advanced cases, radiation therapy. With this approach, cure rates are now 85-90 percent. Nearly all patients undergo surgery as the primary method to remove the tumor. In North America, most patients have the tumor removed at the time of diagnosis. In Europe, most patients receive a few weeks of chemotherapy and then have the tumor removed. Both approaches produce high rates of treatment success.
Tumors that are difficult to remove or bilateral tumors are almost always treated with chemotherapy first to make subsequent surgery easier. There are two major categories of Wilms tumor: favorable (95 percent) and anaplastic (5 percent).
For those with favorable Wilms tumor, the most widely used chemotherapy drugs are vincristine and dactinomycin. Patients with extensive disease or tumor that has spread to distant sites also receive the drug doxorubicin.
Patients with anaplastic Wilms tumor require more intensive chemotherapy, which typically includes the agents vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, and carboplatin. In addition to chemotherapy, patients with extensive disease receive radiation therapy to the affected sites.
Current Research
Current studies are attempting to limit therapy, and its associated side effects, for patients with a low risk of tumor recurrence while increasing therapy for patients with a high risk of tumor recurrence.
For Wilms tumor that has returned after primary treatment, research studies are testing the activity of new drugs and drug combinations. A chemotherapy drug that is being evaluated at St. Jude for recurrent Wilms tumor is topotecan.
Laboratory studies are trying to identify tumors that are more likely to be resistant to therapy.
Investigators are conducting research to determine whether occupational or environmental factors contribute to the development of Wilms tumor.
To view the original of this article Click Here
WAGR & Wilms Tumour
For more details of this complication of Wilms for details of WAGR Click Here However for details specific to WAGR & Wilms Tumour Click Here
Articles
UroToday (KC) 10-Jul-08
- Molecular Evidence of the Independent Origin of Multiple Wilms Tumors in a Case of WAGR
Gazette Live (KC) 09-May-08
Daily Mail (KC) 06-May-08
- Molly Biederman had Wilms Tumour: The heartbreaking friendship between two tiny girls with cancer....
St. Jude 00-Aug-07
- Topotecan shows promise against Wilms Tumor
MedicalNewsToday (KC) 08-Jan-07
- New Gene Associated With Wilms Tumor Found By MGH Cancer Center Researchers
MedicalNewsToday (KC) 02-Dec-06
- New Hope For Children With Wilms Tumour
Blogs
- Pablo's Blog The lively Blog of a young lad with Wilms in America
References
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
